Bruce Brockstein
Research Subjects
Bruce Brockstein has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Abigail J. Harper
NorthShore University HealthSystem, Evanston, IL
1 shared publicationAlexander Lee
1 shared publication- Alexander T.J. Lee
The Christie NHS Foundation Trust, Manchester, United Kingdom
1 shared publication - Andrew Stewart Poklepovic
Virginia Commonwealth University Health System, Richmond, VA
1 shared publication Arun Singh
University of California Los Angeles, Los Angeles, CA
1 shared publication- Athanassios Argiris
Department of Medical Oncology—Head and Neck Surgery, Sidney Kimmel Medical College, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3151-3162
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial
PURPOSE: Desmoid tumors (DTs) are rare, often locally aggressive, connective tissue neoplasms with limited effective treatment options. We evaluated the safety and efficacy of varegacestat, an oral gamma-secretase inhibitor. METHODS: RINGSIDE phase II was an open-label, randomized, dose-finding trial of varegacestat in adults with histologically confirmed DT and disease progression. Participants were randomly assigned 1:1:1 to oral varegacestat 1.2-mg once-daily, 2-mg intermittent (once daily for 2 consecutive days with 5 consecutive days off), or 4-mg intermittent dose. The primary end point was safety. The secondary end point was change in tumor volume from baseline to week 16 per blinded independent central review. At the study end, participants who entered the open-label extension received the selected phase III dose (1.2 mg once daily). RESULTS: In total, 42 participants enrolled in the randomized trial (14 per dose arm). Median varegacestat exposure was 50.5 (range, 3.0-76.0) weeks. Forty-one (97.6%) participants reported treatment-related adverse events (AEs), of which 9 (21.4%) reported grade 3 AEs and none reported serious AEs. There were no grade 4/5 events. The median tumor volume reduction at week 16 was –51.91% for the 1.2-mg once-daily dose, –15.25% for the 2-mg intermittent dose and –9.50% for the 4-mg intermittent dose. The confirmed objective response rate (ORR) was 35.7%, 21.4%, and 21.4%, respectively. Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily (median exposure, 102.0 [range, 3.0-169.0] weeks), the median best percent tumor volume change was –85.88% and the confirmed ORR increased to 57.1%. CONCLUSION: Varegacestat demonstrated clinically meaningful DT volume reduction and ORR with a manageable safety profile across dose regimens. The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3151-3162
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial
PURPOSE: Desmoid tumors (DTs) are rare, often locally aggressive, connective tissue neoplasms with limited effective treatment options. We evaluated the safety and efficacy of varegacestat, an oral gamma-secretase inhibitor. METHODS: RINGSIDE phase II was an open-label, randomized, dose-finding trial of varegacestat in adults with histologically confirmed DT and disease progression. Participants were randomly assigned 1:1:1 to oral varegacestat 1.2-mg once-daily, 2-mg intermittent (once daily for 2 consecutive days with 5 consecutive days off), or 4-mg intermittent dose. The primary end point was safety. The secondary end point was change in tumor volume from baseline to week 16 per blinded independent central review. At the study end, participants who entered the open-label extension received the selected phase III dose (1.2 mg once daily). RESULTS: In total, 42 participants enrolled in the randomized trial (14 per dose arm). Median varegacestat exposure was 50.5 (range, 3.0-76.0) weeks. Forty-one (97.6%) participants reported treatment-related adverse events (AEs), of which 9 (21.4%) reported grade 3 AEs and none reported serious AEs. There were no grade 4/5 events. The median tumor volume reduction at week 16 was –51.91% for the 1.2-mg once-daily dose, –15.25% for the 2-mg intermittent dose and –9.50% for the 4-mg intermittent dose. The confirmed objective response rate (ORR) was 35.7%, 21.4%, and 21.4%, respectively. Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily (median exposure, 102.0 [range, 3.0-169.0] weeks), the median best percent tumor volume change was –85.88% and the confirmed ORR increased to 57.1%. CONCLUSION: Varegacestat demonstrated clinically meaningful DT volume reduction and ORR with a manageable safety profile across dose regimens. The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.
- 4 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (24) , 2647-2655
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
PURPOSE: Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and programmed death ligand-1 (PD-L1) antibody progression awaits robust investigation. Anti-CTLA-4 antibody alone after anti-PD-1/L1 antibody progression has a historical RR of 13%. We report the results of the first prospective clinical trial evaluating ipilimumab 1 mg/kg plus pembrolizumab following progression on anti-PD-1 immunotherapy. METHODS: Patients with advanced melanoma who had progressed on anti-PD-1/L1 antibody as immediate prior therapy (including non–anti-CTLA-4 antibody combinations) were eligible. Patients received pembrolizumab 200 mg plus ipilimumab 1 mg/kg once every 3 weeks for four doses, followed by pembrolizumab monotherapy. The primary end point was RR by irRECIST. After 35 patients, the trial met the primary end point and was expanded to enroll a total of 70 patients to better estimate the RR. RESULTS: Prior treatments included 60 on anti-PD-1 antibody alone and 10 on anti-PD-1/L1 antibody–based combinations. Thirteen patients had progressed in the adjuvant setting. The median length of prior treatment with anti-PD-1/L1 antibody was 4.8 months. Response assessments included five complete and 15 partial responses, making the irRECIST RR 29% among the entire trial population. The median progression-free survival was 5.0 months, and the median overall survival was 24.7 months. The median duration of response was 16.6 months. There was no difference in median time on prior anti-PD1/L1 or time to PD1 + CTLA4 initiation between responders and nonresponders. Grade 3-4 drug-related adverse events occurred in 27% of patients. Responses occurred in PD-L1–negative, non-T-cell–inflamed, and intermediate tumor phenotypes. CONCLUSION: To our knowledge, this is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.
- 4 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (24) , 2647-2655
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
PURPOSE: Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and programmed death ligand-1 (PD-L1) antibody progression awaits robust investigation. Anti-CTLA-4 antibody alone after anti-PD-1/L1 antibody progression has a historical RR of 13%. We report the results of the first prospective clinical trial evaluating ipilimumab 1 mg/kg plus pembrolizumab following progression on anti-PD-1 immunotherapy. METHODS: Patients with advanced melanoma who had progressed on anti-PD-1/L1 antibody as immediate prior therapy (including non–anti-CTLA-4 antibody combinations) were eligible. Patients received pembrolizumab 200 mg plus ipilimumab 1 mg/kg once every 3 weeks for four doses, followed by pembrolizumab monotherapy. The primary end point was RR by irRECIST. After 35 patients, the trial met the primary end point and was expanded to enroll a total of 70 patients to better estimate the RR. RESULTS: Prior treatments included 60 on anti-PD-1 antibody alone and 10 on anti-PD-1/L1 antibody–based combinations. Thirteen patients had progressed in the adjuvant setting. The median length of prior treatment with anti-PD-1/L1 antibody was 4.8 months. Response assessments included five complete and 15 partial responses, making the irRECIST RR 29% among the entire trial population. The median progression-free survival was 5.0 months, and the median overall survival was 24.7 months. The median duration of response was 16.6 months. There was no difference in median time on prior anti-PD1/L1 or time to PD1 + CTLA4 initiation between responders and nonresponders. Grade 3-4 drug-related adverse events occurred in 27% of patients. Responses occurred in PD-L1–negative, non-T-cell–inflamed, and intermediate tumor phenotypes. CONCLUSION: To our knowledge, this is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.
- 1 March 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (3) , 153-155
Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies
- 1 March 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (3) , 153-155
Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies
- 16 July 2015
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 10 (1) , 206-219
Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit
The LIFE Cancer Survivorship Program at NorthShore University HealthSystem provides risk-adapted visits (RAV) facilitated by an oncology nurse during which a survivorship care plan (SCP) is provided and discussed. In this report, we describe and evaluate RAV in promoting individualized health care and self-management during survivorship transition. Patients complete a post-RAV questionnaire at their RAV and another ≥1 year after their RAV. One thousand seven hundred thirteen (1713) RAVs, majority for breast cancer, occurred from January 2007 to March 2014. One thousand six hundred fifteen (1615) “day-of” post-RAV questionnaires were completed. Respondents scaled statements as strongly agree/agree/disagree/strongly disagree. Combined strongly agree/agree ratings are 94 % felt more confident in communicating information about their treatments to other health care providers, 90 % felt more comfortable recognizing signs/symptoms to report to providers, and 98 % had a better appreciation for community programs/services. Of 488 respondents (RAV January 2007 to December 2012 n = 1366) to a questionnaire at least 1 year after the RAV, nearly 100 % found SCP useful to summarize medical information, 97 % to reinforce follow-up, 85 % to recognize symptoms of recurrence, 93 % to identify healthy lifestyle practices, 91 % to assist in identifying resources for support, 72 % discussed their SCP with their healthcare provider, and 97 % made at least one positive lifestyle change. Participation in LIFE RAV following treatment helps survivors to guide future self-care behavior. Data suggest that benefits may persist 1 year after the visit and support the feasibility of a nurse-led RAV to establish a SCP in cancer survivors. Combined provision and discussion of SCPs help survivors construct a useful understanding of their cancer experience and may promote long-term self-management.
- 16 July 2015
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 10 (1) , 206-219
Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit
The LIFE Cancer Survivorship Program at NorthShore University HealthSystem provides risk-adapted visits (RAV) facilitated by an oncology nurse during which a survivorship care plan (SCP) is provided and discussed. In this report, we describe and evaluate RAV in promoting individualized health care and self-management during survivorship transition. Patients complete a post-RAV questionnaire at their RAV and another ≥1 year after their RAV. One thousand seven hundred thirteen (1713) RAVs, majority for breast cancer, occurred from January 2007 to March 2014. One thousand six hundred fifteen (1615) “day-of” post-RAV questionnaires were completed. Respondents scaled statements as strongly agree/agree/disagree/strongly disagree. Combined strongly agree/agree ratings are 94 % felt more confident in communicating information about their treatments to other health care providers, 90 % felt more comfortable recognizing signs/symptoms to report to providers, and 98 % had a better appreciation for community programs/services. Of 488 respondents (RAV January 2007 to December 2012 n = 1366) to a questionnaire at least 1 year after the RAV, nearly 100 % found SCP useful to summarize medical information, 97 % to reinforce follow-up, 85 % to recognize symptoms of recurrence, 93 % to identify healthy lifestyle practices, 91 % to assist in identifying resources for support, 72 % discussed their SCP with their healthcare provider, and 97 % made at least one positive lifestyle change. Participation in LIFE RAV following treatment helps survivors to guide future self-care behavior. Data suggest that benefits may persist 1 year after the visit and support the feasibility of a nurse-led RAV to establish a SCP in cancer survivors. Combined provision and discussion of SCPs help survivors construct a useful understanding of their cancer experience and may promote long-term self-management.
- 6 October 2007
- Published by Springer Nature in Quality of Life Research
- Vol. 16 (10) , 1615-1626
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI). Ninety-eight patients with head and neck cancer were randomized to one of two assessment conditions to evaluate the FHNSI’s context (items administered embedded within the FACT-H&N or as stand-alone scale) and order of administration in the battery. Planned comparisons on the item and scale levels revealed no systematic order or context differences. The embedded and stand-alone versions of the FHNSI showed high internal consistency (Cronbach's alpha 0.79–0.87). Correlations were high between the FHNSI versions and the physical and functional well-being scales of the FACT-H&N (0.70–0.84) and measures of pain intensity (−0.73, −0.74) and depression (−0.71, −0.74); moderate to large with the Performance Status Scale for Head and Neck subscales (PSS-HN; 0.46–0.71); and low with an anxiety measure (0.30, 0.34). Both FHNSI versions differentiated patients grouped by performance status (p < .0001, p < .0001) and global rating of change (p < .0001, p < 0.01). The FHNSI's minimally important difference range was 3–4 points. The FHNSI is a reliable and valid symptom index, which can be administered alone or scored using items embedded within the FACT-H&N.
- 6 October 2007
- Published by Springer Nature in Quality of Life Research
- Vol. 16 (10) , 1615-1626
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI). Ninety-eight patients with head and neck cancer were randomized to one of two assessment conditions to evaluate the FHNSI’s context (items administered embedded within the FACT-H&N or as stand-alone scale) and order of administration in the battery. Planned comparisons on the item and scale levels revealed no systematic order or context differences. The embedded and stand-alone versions of the FHNSI showed high internal consistency (Cronbach's alpha 0.79–0.87). Correlations were high between the FHNSI versions and the physical and functional well-being scales of the FACT-H&N (0.70–0.84) and measures of pain intensity (−0.73, −0.74) and depression (−0.71, −0.74); moderate to large with the Performance Status Scale for Head and Neck subscales (PSS-HN; 0.46–0.71); and low with an anxiety measure (0.30, 0.34). Both FHNSI versions differentiated patients grouped by performance status (p < .0001, p < .0001) and global rating of change (p < .0001, p < 0.01). The FHNSI's minimally important difference range was 3–4 points. The FHNSI is a reliable and valid symptom index, which can be administered alone or scored using items embedded within the FACT-H&N.